Skip to main content
European Commission logo print header

New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH)

Deliverables

KOL Engagement, Communication & Dissemination

Engagement, communication & dissemination of recent development and progress on ATXA’s lead drug NTP42 including with key opinion leaders (KOLs) and other stakeholders of relevance to pulmonary arterial hypertension (PAH).

Publications

Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

Author(s): Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Pedro Mendes-Ferreira, Rui Adão, Carmen Brás-Silva, B. Therese Kinsella
Published in: European Journal of Pharmacology, Issue 889, 2020, Page(s) 173658, ISSN 0014-2999
Publisher: Elsevier BV
DOI: 10.1016/j.ejphar.2020.173658

Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation

Author(s): Eamon P. Mulvaney, Áine G. O'Sullivan, Sarah B. Eivers, Helen M. Reid, B. Therese Kinsella
Published in: Experimental and Molecular Pathology, Issue 110, 2019, Page(s) 104277, ISSN 0014-4800
Publisher: Academic Press
DOI: 10.1016/j.yexmp.2019.104277

NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Author(s): Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Annie Bouchard, Dany Salvail, B. Therese Kinsella
Published in: BMC Pulmonary Medicine, Issue 20/1, 2020, ISSN 1471-2466
Publisher: BioMed Central
DOI: 10.1186/s12890-020-1113-2

NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension

Author(s): T Kinsella, E Mulvaney, HM Reid
Published in: European Respiratory Journal, 2019, Page(s) PA5048
Publisher: European Respiratory Society

Efficacy of the novel thromboxane receptor antagonist NTP42 alone, or in combination with Sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

Author(s): T Kinsella, E Mulvaney, HM Reid
Published in: European Journal of Cardiology, Issue 40, 2019, Page(s) P3670
Publisher: Oxford Academic

Intellectual Property Rights

THROMBOXANE RECEPTOR ANTAGONISTS

Application/Publication number: 16 739541
Date: 2016-06-13
Applicant(s): ATXA THERAPEUTICS LTD

Searching for OpenAIRE data...

There was an error trying to search data from OpenAIRE

No results available